90
Participants
Start Date
October 1, 2025
Primary Completion Date
September 30, 2029
Study Completion Date
September 30, 2029
losartan 25 mg
Losartan is an angiotensin-II inhibitor that modulates the renin-angiotensin system by blocking the activation of angiotensin type 1 receptors, thus preventing binding with angiotensin-II and decreasing blood pressure. Losartan has a broader therapeutic potential for muscle healing and treatment for diseases ranging from rheumatoid arthritis, osteoarthritis, chronic kidney disease, Marfan syndrome, and fatty liver. TGF-β plays an active role in fibrosis leading to the formation of adhesions and scar tissue. By limiting the formation of adhesions and scar tissue, losartan may reduce pain, myofibroblast activity, synovitis, fibrosis, and cartilage degeneration.
Placebo capsule
The placebo capsule will look identical to the active study drug, but will not have any active ingredient and will be filled with corn starch
Mass General Brigham, Foxborough
University of Kentucky
OTHER
Walter Reed National Military Medical Center
FED
Brigham and Women's Hospital
OTHER